SG10201707632PA - Purification of rapamycin derivatives - Google Patents
Purification of rapamycin derivativesInfo
- Publication number
- SG10201707632PA SG10201707632PA SG10201707632PA SG10201707632PA SG10201707632PA SG 10201707632P A SG10201707632P A SG 10201707632PA SG 10201707632P A SG10201707632P A SG 10201707632PA SG 10201707632P A SG10201707632P A SG 10201707632PA SG 10201707632P A SG10201707632P A SG 10201707632PA
- Authority
- SG
- Singapore
- Prior art keywords
- purification
- rapamycin derivatives
- rapamycin
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799857P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201707632PA true SG10201707632PA (en) | 2017-11-29 |
Family
ID=51538094
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507406YA SG11201507406YA (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
SG10202112135VA SG10202112135VA (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
SG10201707632PA SG10201707632PA (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507406YA SG11201507406YA (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
SG10202112135VA SG10202112135VA (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
Country Status (9)
Country | Link |
---|---|
US (5) | US9598439B2 (en) |
EP (1) | EP2972258B1 (en) |
JP (4) | JP2016519086A (en) |
CN (2) | CN105102967B (en) |
CA (1) | CA2901162C (en) |
ES (1) | ES2897473T3 (en) |
HK (1) | HK1218959A1 (en) |
SG (3) | SG11201507406YA (en) |
WO (1) | WO2014145780A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102695542B (en) | 2009-11-02 | 2015-08-12 | 脉冲治疗公司 | For magnetic potential stator system and the method for controlled in wireless magnet rotor |
JP2016519086A (en) | 2013-03-15 | 2016-06-30 | バイオセンサーズ インターナショナル グループ、リミテッド | Purification of rapamycin derivatives |
CN109851626B (en) * | 2019-01-08 | 2021-11-02 | 扬子江药业集团四川海蓉药业有限公司 | Method for separating and purifying temsirolimus |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9713730D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US20060198867A1 (en) * | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
US7452692B2 (en) | 2002-02-13 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Method for extracting a macrolide from biomatter |
ES2229975T1 (en) * | 2003-03-31 | 2005-05-01 | Teva Gyogyszergyar Reszvenytarsasag | CRYSTALLIZATION AND PURIFICATION OF MACROLIDS. |
US7220755B2 (en) * | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
RU2317991C1 (en) * | 2003-12-05 | 2008-02-27 | Байокон Лимитид | Method for isolation and purification of macrolides |
JP4716280B2 (en) * | 2004-03-01 | 2011-07-06 | テルモ株式会社 | Process for producing O-alkylated rapamycin derivatives |
RU2387657C2 (en) * | 2004-04-14 | 2010-04-27 | Вайет | Regiospecific synthesis of rapamycin 42-ester derivatives |
CA2584358A1 (en) | 2004-12-01 | 2006-06-08 | Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag | Non-hygroscopic and powdery amorphous pimecrolimus |
MX2007010716A (en) * | 2005-03-02 | 2008-01-16 | Wyeth Corp | Purification of rapamycin. |
US20060222627A1 (en) * | 2005-03-30 | 2006-10-05 | Andrew Carter | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
BRPI0619592A2 (en) * | 2005-12-07 | 2016-09-06 | Wyeth Corp | methods for measuring particle quality of a rapamycin compound, for determining the average particle size of a sample and the crystallinity of a rapamycin compound, and for rapamycin purification |
US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
GB0601406D0 (en) * | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
EP1993610A2 (en) | 2006-03-07 | 2008-11-26 | Wyeth | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
US7820812B2 (en) * | 2006-07-25 | 2010-10-26 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
US7812032B2 (en) * | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
AU2006350684B2 (en) * | 2006-11-10 | 2012-07-05 | Biocon Limited | A pure form of rapamycin and a process for recovery and purification thereof |
WO2008065887A1 (en) | 2006-11-27 | 2008-06-05 | Terumo Kabushiki Kaisha | Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative |
US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
CN101077334A (en) * | 2007-06-29 | 2007-11-28 | 济南康泉医药科技有限公司 | Anticancer composition containing tyrosine kinase inhibitor |
TW200948361A (en) * | 2008-05-26 | 2009-12-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | Method for synthesizing Biolimus A9 and the like and method for improving stability of the same |
US20100055145A1 (en) * | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
US20100272773A1 (en) | 2009-04-24 | 2010-10-28 | Boston Scientific Scimed, Inc. | Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device |
CN102464669B (en) * | 2010-11-17 | 2014-04-16 | 浙江海正药业股份有限公司 | Amorphous everolimus and preparation method thereof |
US8669360B2 (en) * | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
CN102786534A (en) * | 2012-05-25 | 2012-11-21 | 上海现代制药股份有限公司 | Preparation method of everolimus |
JP2016519086A (en) | 2013-03-15 | 2016-06-30 | バイオセンサーズ インターナショナル グループ、リミテッド | Purification of rapamycin derivatives |
-
2014
- 2014-03-17 JP JP2016503426A patent/JP2016519086A/en not_active Withdrawn
- 2014-03-17 CA CA2901162A patent/CA2901162C/en active Active
- 2014-03-17 SG SG11201507406YA patent/SG11201507406YA/en unknown
- 2014-03-17 EP EP14763326.7A patent/EP2972258B1/en active Active
- 2014-03-17 CN CN201480013252.6A patent/CN105102967B/en active Active
- 2014-03-17 SG SG10202112135VA patent/SG10202112135VA/en unknown
- 2014-03-17 WO PCT/US2014/030602 patent/WO2014145780A1/en active Application Filing
- 2014-03-17 ES ES14763326T patent/ES2897473T3/en active Active
- 2014-03-17 SG SG10201707632PA patent/SG10201707632PA/en unknown
- 2014-03-17 CN CN201811056060.XA patent/CN108864149B/en active Active
-
2015
- 2015-09-14 US US14/853,711 patent/US9598439B2/en active Active
-
2016
- 2016-06-17 HK HK16107001.4A patent/HK1218959A1/en unknown
-
2017
- 2017-02-02 US US15/422,593 patent/US10202402B2/en active Active
-
2018
- 2018-12-18 US US16/224,140 patent/US10597406B2/en active Active
-
2019
- 2019-03-07 JP JP2019041615A patent/JP2019089848A/en active Pending
-
2020
- 2020-03-02 US US16/806,770 patent/US11046711B2/en active Active
-
2021
- 2021-05-06 JP JP2021078418A patent/JP2021121601A/en active Pending
- 2021-06-28 US US17/360,973 patent/US11780850B2/en active Active
-
2023
- 2023-08-25 JP JP2023136964A patent/JP2023164476A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023164476A (en) | 2023-11-10 |
US11780850B2 (en) | 2023-10-10 |
JP2021121601A (en) | 2021-08-26 |
HK1218959A1 (en) | 2017-03-17 |
US20170334928A1 (en) | 2017-11-23 |
US9598439B2 (en) | 2017-03-21 |
CA2901162C (en) | 2021-06-01 |
CA2901162A1 (en) | 2014-09-18 |
JP2019089848A (en) | 2019-06-13 |
EP2972258A4 (en) | 2016-12-21 |
WO2014145780A1 (en) | 2014-09-18 |
ES2897473T3 (en) | 2022-03-01 |
US10202402B2 (en) | 2019-02-12 |
US20190256527A1 (en) | 2019-08-22 |
SG10202112135VA (en) | 2021-12-30 |
US20200270272A1 (en) | 2020-08-27 |
US20220024947A1 (en) | 2022-01-27 |
EP2972258B1 (en) | 2021-08-04 |
CN108864149B (en) | 2022-04-05 |
WO2014145780A4 (en) | 2014-11-20 |
US20160002262A1 (en) | 2016-01-07 |
CN105102967A (en) | 2015-11-25 |
SG11201507406YA (en) | 2015-10-29 |
JP2016519086A (en) | 2016-06-30 |
US11046711B2 (en) | 2021-06-29 |
CN105102967B (en) | 2018-10-12 |
US10597406B2 (en) | 2020-03-24 |
EP2972258A1 (en) | 2016-01-20 |
CN108864149A (en) | 2018-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221466A1 (en) | Bipyrazole derivatives as jak inhibitors jak | |
PL2803401T3 (en) | Purification of air | |
HRP20181710T1 (en) | Use of benzimidazole-proline derivatives | |
AR092198A1 (en) | DERIVATIVES OF PIRAZOLOPIRIMIDINAS | |
HK1216429A1 (en) | Methods for purification of rylsulfatase | |
ZA201602198B (en) | Preparation of hydroxy-benzylbenzene derivatives | |
EP2948557A4 (en) | Purification of cadaverine | |
ZA201602831B (en) | Use of lactones | |
HK1213566A1 (en) | Novel tetrazolone derivatives | |
HK1218959A1 (en) | Purification of rapamycin derivatives | |
HK1218118A1 (en) | Low temperature synthesis of rapamycin derivatives | |
GB201314581D0 (en) | Purification |